Small victories.
As anticipated, the FDA has approved Pfizer’s reduced-dose COVID-19 vaccine for children ages 5-11, with a reported efficacy of over 90% in preventing illness. | FDA 2021
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
As anticipated, the FDA has approved Pfizer’s reduced-dose COVID-19 vaccine for children ages 5-11, with a reported efficacy of over 90% in preventing illness. | FDA 2021
Comments
Post a Comment